ADMA
ADMA Biologics, Inc.
stockNASDAQ
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma's lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 11.41 | 2026-10-30 | +11.70% | -5.390 |
| 1M | 10.18 | 2026-10-06 | +25.19% | -3.415 |
| 3M | 10.06 | 2026-08-06 | +26.69% | -2.280 |
| 6M | 10.08 | 2026-05-06 | +26.43% | -1.238 |
| 1Y | 14.03 | 2025-11-06 | -9.16% | -0.054 |
| 2Y | 19.67 | 2024-11-06 | -35.21% | — |
| 5Y | 1.36 | 2021-11-05 | +837.10% | 1.053 |
ADMA Biologics, Inc. (NASDAQ:ADMA) stock price today is $12.74, and today's volume is 3,770,621. ADMA is down 3.523% today. The 30 day average volume is 3.70M. ADMA market cap is $2.85B with 223.98M shares outstanding.